JP2023523319A - シュードモナス感染症を処置するためのバクテリオファージ組成物 - Google Patents

シュードモナス感染症を処置するためのバクテリオファージ組成物 Download PDF

Info

Publication number
JP2023523319A
JP2023523319A JP2022565563A JP2022565563A JP2023523319A JP 2023523319 A JP2023523319 A JP 2023523319A JP 2022565563 A JP2022565563 A JP 2022565563A JP 2022565563 A JP2022565563 A JP 2022565563A JP 2023523319 A JP2023523319 A JP 2023523319A
Authority
JP
Japan
Prior art keywords
seq
bacteriophage
polynucleotide sequence
identity
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523319A5 (enExample
Inventor
ルミール，セバスチャン
コラール，ステイシー・リン
バーナム，ブライアン・クラーク
Original Assignee
アルマタ・ファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルマタ・ファーマシューティカルズ・インコーポレーテッド filed Critical アルマタ・ファーマシューティカルズ・インコーポレーテッド
Publication of JP2023523319A publication Critical patent/JP2023523319A/ja
Publication of JP2023523319A5 publication Critical patent/JP2023523319A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022565563A 2020-04-27 2021-04-27 シュードモナス感染症を処置するためのバクテリオファージ組成物 Pending JP2023523319A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016132P 2020-04-27 2020-04-27
US63/016,132 2020-04-27
PCT/US2021/029412 WO2021222257A1 (en) 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection

Publications (2)

Publication Number Publication Date
JP2023523319A true JP2023523319A (ja) 2023-06-02
JP2023523319A5 JP2023523319A5 (enExample) 2024-05-13

Family

ID=76284135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565563A Pending JP2023523319A (ja) 2020-04-27 2021-04-27 シュードモナス感染症を処置するためのバクテリオファージ組成物

Country Status (8)

Country Link
US (3) US12594312B2 (enExample)
EP (1) EP4142760A1 (enExample)
JP (1) JP2023523319A (enExample)
CN (1) CN116018154A (enExample)
AU (1) AU2021263735A1 (enExample)
CA (1) CA3179361A1 (enExample)
IL (1) IL296741A (enExample)
WO (1) WO2021222257A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025143108A1 (ja) * 2023-12-27 2025-07-03 株式会社Arrowsmith 緑膿菌バクテリオファージ

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US12594312B2 (en) * 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection
WO2025219447A1 (en) 2024-04-17 2025-10-23 Hun-Ren Biological Research Centre Szeged Region-specific phage compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537405A (ja) * 2013-10-25 2016-12-01 フレシード・ファルマＰｈｅｒｅｃｙｄｅｓ Ｐｈａｒｍａ シュードモナス感染症のファージ治療
JP2017534684A (ja) * 2014-11-07 2017-11-24 フレシード・ファルマＰｈｅｒｅｃｙｄｅｓ Ｐｈａｒｍａ ファージセラピー
WO2019136108A1 (en) * 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Bacteriophage compositions for treating pseudomonas infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2833899T3 (da) * 2012-03-19 2020-09-28 Tecnifar Ind Tecnica Farmaceutica S A Sammensætninger, der omfatter cocktails af antibakterielle fager, og anvendelser deraf til behandling af bakterieinfektioner
US11672839B2 (en) * 2016-12-05 2023-06-13 Technechnophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
WO2018151416A1 (ko) * 2017-02-17 2018-08-23 주식회사 인트론바이오테크놀로지 신규한 녹농균 박테리오파지 Pse-AEP-3 및 이의 녹농균 증식 억제 용도
US12594312B2 (en) 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537405A (ja) * 2013-10-25 2016-12-01 フレシード・ファルマＰｈｅｒｅｃｙｄｅｓ Ｐｈａｒｍａ シュードモナス感染症のファージ治療
JP2017534684A (ja) * 2014-11-07 2017-11-24 フレシード・ファルマＰｈｅｒｅｃｙｄｅｓ Ｐｈａｒｍａ ファージセラピー
WO2019136108A1 (en) * 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Bacteriophage compositions for treating pseudomonas infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CEYSSENS, PIETER-JAN ET AL.: ""Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aerugin", ENVIRON. MICROBIOL., vol. 11, JPN6025018873, 2009, pages 2874 - 2883, ISSN: 0005590877 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025143108A1 (ja) * 2023-12-27 2025-07-03 株式会社Arrowsmith 緑膿菌バクテリオファージ

Also Published As

Publication number Publication date
CN116018154A (zh) 2023-04-25
US20230174954A1 (en) 2023-06-08
IL296741A (en) 2022-11-01
CN116018154A9 (zh) 2023-10-24
US20240226205A1 (en) 2024-07-11
AU2021263735A1 (en) 2022-10-27
WO2021222257A1 (en) 2021-11-04
US12594312B2 (en) 2026-04-07
US20210330722A1 (en) 2021-10-28
CA3179361A1 (en) 2021-11-04
EP4142760A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
JP2023523319A (ja) シュードモナス感染症を処置するためのバクテリオファージ組成物
US12239677B2 (en) Therapeutic bacteriophage compositions for treating Staphylococcus infection
JP7449967B2 (ja) 療法バクテリオファージ組成物
US20250170195A1 (en) Bacteriophage compositions for treating pseudomonas infections
JP7812496B2 (ja) 呼吸器抗菌性ファージを含むカクテル組成物及びその使用方法
Rezaei Bacteriophages for the treatment of resistant bacterial infectious diseases
HK40092898A (zh) 用於治疗假单胞菌属感染的噬菌体组合物
CA3157249C (en) Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof
AU2019205241C1 (en) Bacteriophage compositions for treating Pseudomonas infections
HK40040296A (en) Therapeutics bacteriophage compositions for treating staphylococcus infection
JP2023513934A (ja) ブドウ球菌感染症を処置するためのバクテリオファージ組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260224